Chu joins Abingworth's US team
This article was originally published in Clinica
Executive Summary
Life sciences investor Abingworth has expanded its US team with the addition of Shelley Chu as a partner. Chu is a trained doctor and has over 20 years experience in venture capital, business development and strategic leadership. She was most recently at pharma company Gilead Sciences, prior to that, she has worked at Frazier Healthcare Ventures and Flagship Ventures. At Abingworth, Chu will source and manage deals at across a broad range of therapeutic areas and stages of development. Abingworth has investments on both sides of the Atlantic and in pharma and medtech. Its active medtech deals include ophthalmic technology company Avedro and medical imaging firm MEDIAN Technologies.